Transforming Macrocycle Synthesis for Pharmaceutical Innovation
At Apeiron, we specialize in advanced synthetic chemistry solutions that accelerate pharmaceutical innovation. One of our core capabilities is the design and synthesis of complex macrocycles using state-of-the-art metathesis technologies. As macrocyclic drugs and heterocyclic scaffolds continue to transform the landscape of modern medicinal chemistry, our expertise in ring-closing metathesis (RCM), macrocyclization, and green metathesis enables our partners to move from concept to candidate with unmatched efficiency.
Metathesis as a Strategic Tool in Macrocyclization
Ring-closing metathesis is a cornerstone technique for constructing medium- and large-sized rings—structures that are notoriously difficult to access using traditional methods. With exceptional functional-group tolerance and predictable outcomes, RCM provides a reliable platform for creating drug-like macrocycles, conformationally constrained scaffolds, and stable cyclic intermediates essential to pharmaceutical R&D.
At Apeiron, we combine deep mechanistic insight with practical know-how in catalyst design. This ensures high-performing macrocyclizations even for structurally complex targets, enabling medicinal chemists to rapidly explore macrocycles in drug discovery with confidence and speed.
Can peptide macrocycles and metathesis-stabilized scaffolds become the future of next-generation therapeutics?
Peptide-derived macrocycles have become a major focus in next-generation therapeutics due to their ability to bridge the gap between small molecules and biologics. Apeiron technology can be applied to peptide macrocyclization via metathesis, including peptide stapling, backbone-to-side-chain closure, and hydrocarbon-based constraints. These methods enhance binding affinity, cell permeability, metabolic stability, and selectivity.
With Apeiron’s metathesis-driven approach, peptide macrocycles become more accessible, scalable, and tunable.
RCM in the Synthesis of Clinically Relevant Macrocyclic Agents: The Case of HCV Inhibitors
RCM has played a transformative role in synthesizing high-value macrocyclic pharmaceuticals, including hepatitis C virus (HCV) inhibitors. A landmark example is the macrocyclization step in the synthesis of Ciluprevir, a potent HCV NS3 protease inhibitor, where ring-closing metathesis enabled the efficient construction of the key macrocyclic core. Although Ciluprevir failed in clinical trials, nevertheless, its synthesis remains important as the first commercially viable large-scale RCM macrocyclization that influenced a number of subsequent synthetic approaches to other anti-HCV macrocycles.
This iconic use case illustrates how RCM can streamline access to highly functionalized macrocyclic structures central to antiviral drug development.
For HCV inhibitors see: Org. Lett., Vol. 15, No. 5, 2013;
Org. Process Res. Dev. 2009, 13, 2, 250–254;
Org. Process Res. Dev. 2005, 9, 4, 513–515
Green Metathesis for Sustainable and Scalable Synthesis
Sustainability is integral to the Apeiron philosophy. Our green metathesis practices incorporate low-impact solvents, and energy-efficient conditions. Because olefin metathesis is inherently atom-economic, it aligns naturally with green chemistry principles—reducing waste while maintaining high-performance synthesis.
For companies building environmentally responsible drug pipelines, Apeiron provides a forward-looking synthetic platform that combines efficiency, scalability, and sustainability.
How can we enable better Macrocycles in Drug Discovery?
Macrocycles are now central to targeting historically “undruggable” proteins. Their unique 3D architectures allow them to access binding sites unavailable to traditional small molecules. By offering cutting-edge macrocyclization, macrocycle optimization, and metathesis-based scaffold design, Apeiron empowers discovery teams to expand chemical space, enhance molecular diversity, and accelerate lead identification.
More on macrocycles in drug discovery [J. Med. Chem. 2023, 66, 8, 5377–5396]